uniQure N.V. (UQ1.F) News
Track canonical SquawkNews coverage tagged to UQ1.F, uniQure N.V.. This hub brings together deduplicated headlines about frankfurt, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 3 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
UniQure’s Huntington’s gene therapy AMT-130 fails to slow disease progression significantly
UniQure said its gene therapy AMT-130 missed statistical significance on the main goal of slowing Huntington’s disease progression in a four-year analysis, with 44% slowing at 48 months in 12 high-dose patients versus an
EARNINGS | Sep 29, 2026, 11:55 AM UTC
M
uniQure follow-up AMT-130 Phase I/II data show 80% slowing at 36 months in high-dose patients
uniQure said follow-up Phase I/II results for AMT-130 in Huntington’s extended to 48 months, with high-dose patients showing 80% slowing at 36 months versus an external natural-history comparator; functional benefit was
EARNINGS | Sep 29, 2026, 11:45 AM UTC
M
UniQure Huntington's therapy does not reach statistical significance in trial
UniQure said its Huntington's treatment slowed disease progression by 44% but did not reach statistical significance in an ongoing early-to-mid-stage trial.
EARNINGS | Sep 29, 2026, 11:37 AM UTC